- Home
- BTO vs AUTL Comparison
BTO vs AUTL Comparison
Compare BTO & AUTL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BTO
- AUTL
- Stock Information
- Founded
- BTO 1994
- AUTL 2014
- Country
- BTO United States
- AUTL United Kingdom
- Employees
- BTO N/A
- AUTL N/A
- Industry
- BTO Investment Managers
- AUTL Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- BTO Finance
- AUTL Health Care
- Exchange
- BTO Nasdaq
- AUTL Nasdaq
- Market Cap
- BTO 746.3M
- AUTL 625.4M
- IPO Year
- BTO N/A
- AUTL 2018
- Fundamental
- Price
- BTO $37.62
- AUTL $1.46
- Analyst Decision
- BTO
- AUTL Strong Buy
- Analyst Count
- BTO 0
- AUTL 5
- Target Price
- BTO N/A
- AUTL $9.12
- AVG Volume (30 Days)
- BTO 54.2K
- AUTL 3.8M
- Earning Date
- BTO 01-01-0001
- AUTL 08-12-2025
- Dividend Yield
- BTO 9.13%
- AUTL N/A
- EPS Growth
- BTO N/A
- AUTL N/A
- EPS
- BTO N/A
- AUTL N/A
- Revenue
- BTO N/A
- AUTL $29,934,000.00
- Revenue This Year
- BTO N/A
- AUTL $634.25
- Revenue Next Year
- BTO N/A
- AUTL $93.16
- P/E Ratio
- BTO N/A
- AUTL N/A
- Revenue Growth
- BTO N/A
- AUTL 185.17
- 52 Week Low
- BTO $22.95
- AUTL $1.11
- 52 Week High
- BTO $32.81
- AUTL $5.00
- Technical
- Relative Strength Index (RSI)
- BTO 65.49
- AUTL 27.33
- Support Level
- BTO $37.00
- AUTL $1.39
- Resistance Level
- BTO $37.80
- AUTL $1.55
- Average True Range (ATR)
- BTO 0.54
- AUTL 0.10
- MACD
- BTO 0.15
- AUTL -0.02
- Stochastic Oscillator
- BTO 87.72
- AUTL 14.00
About BTO John Hancock Financial Opportunities Fund
John Hancock Financial Opportunities Fund is the United States based closed-end, diversified management investment company. Its investment objective is to provide a high level of total return consisting of long-term capital appreciation and current income. The company invests in banks, capital markets, Insurance, Mortage Real Estate Investment trust, Health Care REITs, Diversified REITs, Office REITs.
About AUTL Autolus Therapeutics plc
Autolus Therapeutics PLC is a biopharmaceutical company developing next-generation programmed T-cell therapies for the treatment of cancer. The company's clinical-stage pipeline comprises Obe-cel (obecabtagene autoleucel), AUTO1/22, AUTO3, AUTO5, AUTO6, AUTO7 & AUTO8.